NO20054260L - Disepergebar formulering av en anti-inflammatorisk forbindelse - Google Patents

Disepergebar formulering av en anti-inflammatorisk forbindelse

Info

Publication number
NO20054260L
NO20054260L NO20054260A NO20054260A NO20054260L NO 20054260 L NO20054260 L NO 20054260L NO 20054260 A NO20054260 A NO 20054260A NO 20054260 A NO20054260 A NO 20054260A NO 20054260 L NO20054260 L NO 20054260L
Authority
NO
Norway
Prior art keywords
inflammatory compound
inflammatory agent
dispersible
dispersible formulation
inflammatory
Prior art date
Application number
NO20054260A
Other languages
English (en)
Other versions
NO20054260D0 (no
Inventor
Niki Ann Waldron
Nancy Jean Britten
John W Burns
John W Hallberg
Jeffrey L Watts
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NO20054260D0 publication Critical patent/NO20054260D0/no
Publication of NO20054260L publication Critical patent/NO20054260L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives en fremgangsmåte for behandling av en inflammatorisk tilstand i et væskeholdig organ som har en naturlig utløpsåpning, så som juret til et melkeproduserende dyr, eller et øre. Fremgangsmåten omfatter administrering til organet via utløpsåpningen, av en farmasøytisk blanding som omfatter et antiinflammatorisk middel og en bærer som omfatter en amfipatisk olje som er vanndispergerbar og uløselig i etanol, mikrokrystallinsk voks og en farmasøytisk akseptabel ikke-vandig bærer. Dessuten tilveiebringes en slik blanding som omfatter det antiinflammatoriske middel. Blandingen er lett dispergerbar i væsken i det væskeholdige organ.
NO20054260A 2003-03-20 2005-09-15 Disepergebar formulering av en anti-inflammatorisk forbindelse NO20054260L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45632503P 2003-03-20 2003-03-20
PCT/IB2004/000826 WO2004082588A2 (en) 2003-03-20 2004-03-10 Dispersible formulation of an anti-inflammatory agent

Publications (2)

Publication Number Publication Date
NO20054260D0 NO20054260D0 (no) 2005-09-15
NO20054260L true NO20054260L (no) 2005-12-12

Family

ID=33030094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054260A NO20054260L (no) 2003-03-20 2005-09-15 Disepergebar formulering av en anti-inflammatorisk forbindelse

Country Status (26)

Country Link
US (1) US20040235803A1 (no)
EP (1) EP1608407B1 (no)
JP (1) JP2006520779A (no)
KR (1) KR100717433B1 (no)
CN (1) CN1761487A (no)
AR (1) AR043650A1 (no)
AT (1) ATE337793T1 (no)
AU (1) AU2004222523A1 (no)
BR (1) BRPI0408556A (no)
CA (1) CA2519125A1 (no)
CL (1) CL2004000573A1 (no)
CO (1) CO5611169A2 (no)
CY (1) CY1105652T1 (no)
DE (1) DE602004002201T2 (no)
DK (1) DK1608407T3 (no)
ES (1) ES2270361T3 (no)
MX (1) MXPA05009978A (no)
NO (1) NO20054260L (no)
PL (1) PL1608407T3 (no)
PT (1) PT1608407E (no)
RU (1) RU2325189C2 (no)
SI (1) SI1608407T1 (no)
TW (1) TWI262084B (no)
UY (1) UY28235A1 (no)
WO (1) WO2004082588A2 (no)
ZA (1) ZA200506920B (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
RU2323019C1 (ru) * 2006-11-23 2008-04-27 Государственное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Федерального агентства по здравоохранению и социальному развитию Способ лечения больных с посттравматической сенсоневральной тугоухостью в остром периоде, возникшей в результате минно-взрывной травмы
RU2356556C1 (ru) * 2007-11-21 2009-05-27 ФГОУ ВПО Уральская государственная сельскохозяйственная академия (УрГСХА), ОНРИ Средство для лечения воспалений и травм молочной железы у коров
US9943614B2 (en) 2008-06-17 2018-04-17 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CN104053458B (zh) 2011-07-20 2016-07-20 布莱阿姆青年大学 包含洗脱塞拉集宁化合物的水凝胶材料
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
KR20140116111A (ko) 2011-12-21 2014-10-01 브라이엄 영 유니버시티 구강 관리 조성물
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
US10039285B2 (en) 2012-05-02 2018-08-07 Brigham Young University Ceragenin particulate materials and methods for making same
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
EP2908826A1 (en) * 2012-10-17 2015-08-26 Brigham Young University Treatment and prevention of mastitis
JP6294352B2 (ja) 2013-01-07 2018-03-14 ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍ Ｙｏｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 細胞増殖を減少させ、ある特定の疾患を治療する方法
US11491105B2 (en) * 2013-02-08 2022-11-08 Luoda Pharma Limited Methods of treating microbial infections, including mastitis
WO2014151411A1 (en) 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3574985A1 (en) 2013-12-20 2019-12-04 President And Fellows Of Harvard College Organomimetic devices and methods of use and manufacturing thereof
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
RU2557691C1 (ru) * 2014-07-25 2015-07-27 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический Центр оториноларингологии им Л.И. Свержевского" Департамента здравоохранения города Москвы Способ определения длительности лечения активных форм отосклероза
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104688554A (zh) * 2015-01-30 2015-06-10 柳州两面针股份有限公司 水杨苷在制备口腔护理保健品中的应用
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
KR101625020B1 (ko) 2016-02-11 2016-06-01 최예도 식기세척기
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
WO2019050340A2 (ko) * 2017-09-08 2019-03-14 동국제약 주식회사 아보카도 오일 분획을 유효성분으로 포함하는 난청의 예방 또는 치료용 약학적 조성물
ES2985441T3 (es) 2018-07-30 2024-11-05 Virbac Utilización novedosa de glucocorticoides para el tratamiento de infecciones microbianas epiteliales de un órgano que contiene fluidos con un orificio exterior natural en mamíferos
US12186328B2 (en) 2019-05-23 2025-01-07 Brigham Young University Use of CSA compounds to stimulate stem cells and hair growth

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1181527A (en) * 1966-09-21 1970-02-18 Douglas Gabriel Parizeau Composition and Method for Treating Mastitis with Therapeutic Agents.
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
IT1190445B (it) * 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
EP0828717B1 (en) * 1995-05-25 2002-09-04 G.D. SEARLE & CO. Method of preparing 3-haloalkyl-1h-pyrazoles
NZ309624A (en) * 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
ATE233743T1 (de) * 1996-04-12 2003-03-15 Searle & Co N-((4-(5-methyl-3-phenylisoxazol-4- yl)phenyl)sulphonylpropylamid und sein natriumsalz als pro-pharmakon von cox-2 inhibitoren
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
ME00855B (me) * 1997-12-03 2008-08-07 Merck & Co Inc Injektibilne formulacije dugog dejstva koje sadrže hidrogenisano ricinusovo ulje
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
AP2002002582A0 (en) * 1999-12-23 2002-09-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
EP1712239A3 (en) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US20020188016A9 (en) * 2000-06-08 2002-12-12 Peterson Johnny W. Heterocycle derivatives and methods of use
CA2410632A1 (en) * 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
NO20054260D0 (no) 2005-09-15
PL1608407T3 (pl) 2006-12-29
UY28235A1 (es) 2004-11-08
WO2004082588A3 (en) 2004-12-23
JP2006520779A (ja) 2006-09-14
TW200503756A (en) 2005-02-01
EP1608407B1 (en) 2006-08-30
CN1761487A (zh) 2006-04-19
DE602004002201T2 (de) 2007-09-20
CO5611169A2 (es) 2006-02-28
RU2005129266A (ru) 2006-03-20
SI1608407T1 (sl) 2006-12-31
WO2004082588A2 (en) 2004-09-30
KR100717433B1 (ko) 2007-05-14
CA2519125A1 (en) 2004-09-30
DK1608407T3 (da) 2006-12-04
CL2004000573A1 (es) 2005-01-14
PT1608407E (pt) 2006-12-29
US20040235803A1 (en) 2004-11-25
CY1105652T1 (el) 2010-12-22
AR043650A1 (es) 2005-08-03
MXPA05009978A (es) 2005-11-04
AU2004222523A1 (en) 2004-09-30
EP1608407A2 (en) 2005-12-28
RU2325189C2 (ru) 2008-05-27
DE602004002201D1 (de) 2006-10-12
ZA200506920B (en) 2007-09-26
BRPI0408556A (pt) 2006-03-21
ATE337793T1 (de) 2006-09-15
ES2270361T3 (es) 2007-04-01
TWI262084B (en) 2006-09-21
KR20050114249A (ko) 2005-12-05

Similar Documents

Publication Publication Date Title
NO20054260L (no) Disepergebar formulering av en anti-inflammatorisk forbindelse
NO20054777L (no) Dispergerbar farmasoytisk sammesetning for behandling av mastitt og/eller otittforstyrrelser
NO20052306L (no) Dispergerbare farmasoytiske blandinger.
CN114206312A (zh) 用于治疗炎性皮肤病的局部组合物和方法
NO20060982L (no) Dispergerende formulering for et anti-inflammatorisk middel
EP2124922B1 (en) Composition comprising rutin and polyunsaturated fatty acid having an inhibitory activity on 5 alpha-reductase
JPS6322015A (ja) 局所適用のための医薬製剤
JP6456533B2 (ja) ロキソプロフェン含有外用剤組成物
NO20071354L (no) anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.
JP4684404B2 (ja) 消炎鎮痛外用剤組成物
BRPI1004113A2 (pt) composiÇço de peràxido de benzoÍla para tratamento de pele
KR20050033671A (ko) 손톱용 항진균 외용제
JP4880813B2 (ja) 外用消炎鎮痛剤組成物
MXPA04007082A (es) Composiciones topicas que tienen un ingrediente natural y metodo de uso.
NO20071160L (no) Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel
FR3015291A1 (fr) Composition antiprurigineuse
NO20083784L (no) Nytt sitratsalt av en indol derivativ og den farmasoytiske bruken derav
KR101270929B1 (ko) 섬오갈피 근피 성분인 아칸토산을 이용한 피부 미백제 조성물
US20100010078A1 (en) Methods of treating androgen dependent prostate cancer by administering an active pharmaceutical ingredient being fisetin, 3,3',4',7-tetrahydroxyflavone or a derivative thereof, in an oral, transdermal or topical dosage form
JP2008069109A (ja) 外用医薬組成物
WO2015012521A1 (ko) 여드름 치료, 예방 또는 개선에 유효한 클로린 e6
KR20080096175A (ko) 여드름 개선용 외용제 조성물
AU2017380471B2 (en) Topical formulation comprising green lipped mussel and honey
NO20061354L (no) Fremgangsmater og sammensetninger for oral administrering av prodroger av protonpumpe inhibitatorer
KR20120127346A (ko) 섬오갈피 근피 성분인 아칸토산을 이용한 피부 미백제 조성물

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application